At this time, Legacy Healthcare does not have a program to provide its investigational therapy Cinainu (LH-8) to Alopecia Areata patients on an expanded access basis pursuant to section 561(b) of the U.S. Federal Food, Drug, and Cosmetic Act (FDCA).

In the meantime, we invite you to register your interest and we will inform you when the company is either in position to make its investigational therapy Cinainu available on an expanded access basis or when Phase 3 clinical trial starts enrollment.